IBIO.O (IBIO.O) News
Follow IBIO.O (IBIO.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
BRIEF — iBio — IBIO — 610 Plus Semaglutide Preserves Lean Mass In Eight — Week Obese NHP Study
Oct 13 (Reuters) — iBio Inc: Ibio - Ibio-610 Plus Semaglutide Preserves Lean Mass In Eight-week Obese Nhp Study Ibio - Ibio-610 Demonstrates 97% Reduction In Active Activin E At Week 8 In Nhp Study Ibio - Expects To Star
NEWS | Oct 13, 2026, 12:11 PM UTC
L
iBio plans first — in — human trial of obesity drug candidate IBIO — 610 in H1 2027
iBio highlighted preclinical data on IBIO-610 from an obese non-human primate study, with results already presented at EASD on Oct. 1, 2026. In combination with semaglutide, IBIO-610 shifted weight loss toward fat, sugge
NEWS | Oct 13, 2026, 11:06 AM UTC